- 
        Another step towards a smoke-free future
      
- 
        €490 million planned investment.
      
- 
        300 new jobs to be created
      
    LAUSANNE, Switzerland--(BUSINESS WIRE)--Jul. 25, 2017--
      Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) is
      planning to invest approximately €490 million to transform its cigarette
      production factory in Otopeni, near Bucharest, Romania into a high-tech
      facility to manufacture HEETS, the tobacco units used with the
      electronic tobacco heating device IQOS.
    
      The conversion of the factory into a HEETS production facility
      has already commenced and is expected to be completed and fully
      operational by 2020.
    
      The investment will create about 300 additional jobs for highly-skilled
      employees at the Romanian facility, which currently employs
      approximately 600 people.
    
      Romania will join a growing list of countries where PMI manufactures
      heated tobacco units for IQOS. Earlier this month, PMI announced
      plans to install two new high-tech production lines in Neuchâtel,
      Switzerland, to produce HEETS.
    
      In June, PMI announced it would expand capacity at the company’s
      heated tobacco unit manufacturing facility in Bologna, Italy and also
      announced plans to build a new facility for HEETS in Dresden,
      Germany. In addition, PMI will also convert its cigarette factories in
      Greece and Russia and by the end of 2018, PMI plans to have a total
      annual installed capacity of approximately 100 billion heated tobacco
      units.
    
      IQOS and HEETS have been available for adult smokers in
      Bucharest since November 2015 and in 16 cities throughout Romania from
      the beginning of this year. IQOS is currently available in key
      cities in more than 27 markets around the world and is expected to be
      available in 30-35 markets, either key cities or nationwide by the end
      of 2017, as capacity permits.
    
      Commenting on this announcement, André Calantzopoulos, PMI’s Chief
      Executive Officer, said:
    
      “Our investment in Romania further demonstrates our commitment to a
      future in which smoke-free products ultimately replace cigarettes. We
      are encouraged by the 2.9 million smokers around the world who have
      already given up smoking and switched to IQOS. We expect this momentum
      to continue and the conversion of the Romanian facility will help us to
      meet the growing demand from adult smokers for better alternatives to
      cigarettes.”
    
      IQOS is one of four scientifically substantiated smoke-free
      product platforms that PMI is developing to address adult smoker demand
      for better alternatives to cigarettes.
    
      Since 2008, PMI has hired more than 400 scientists and experts and
      invested over USD 3 billion in research, product development and
      scientific substantiation for smoke-free products. The company openly
      shares its scientific methodologies and findings for independent
      third-party review and verification, and has published its research in
      over 200 articles and book chapters since 2011. Results of scientific
      research conducted by PMI to date indicate that IQOS is likely to
      reduce the risk of harm compared to cigarette smoking, and is a better
      choice for those who would otherwise continue to smoke.
    
      Philip Morris International Inc.
    
      Philip Morris International Inc. (PMI) is the world’s leading
      international tobacco company, with six of the world's top 15
      international brands and products sold in more than 180 markets. In
      addition to the manufacture and sale of cigarettes, including Marlboro,
      the number one global cigarette brand, and other tobacco products, PMI
      is engaged in the development and commercialization of reduced-risk
      products (RRPs). RRPs is the term PMI uses to refer to products that
      present, are likely to present, or have the potential to present less
      risk of harm to smokers who switch to these products versus continued
      smoking. Through multidisciplinary capabilities in product development,
      state-of-the-art facilities, and industry-leading scientific
      substantiation, PMI aims to provide an RRP portfolio that meets a broad
      spectrum of adult smoker preferences and rigorous regulatory
      requirements. For more information, see www.pmi.com
      and www.pmiscience.com.
    
    

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005614/en/
Source: Philip Morris International
      Philip Morris International
Media Office
T: +41 (0)58
      242 4500
E: media@pmi.com